Vet-Stem, Inc. Proudly Announces Distribution Partnership with Animal Health International, Inc. for Regenerative Cell Therapies|
November 14, 2013 --
Animal Health International, Inc. the premier animal health distribution company in North America, and Vet-Stem, Inc., the leading Regenerative Veterinary Medicine company, announce their partnership to offer stem cell therapy and platelet rich plasma (PRP) kits to equine veterinarians nationwide. Vet-Stem’s GenesisCS-2 PRP Kit and stem cell services bring innovative new therapies to the diverse artillery of products and supplies Animal Health International provides to the equine industry.
Vet-Stem's Regenerative Veterinary Medicine includes stem cell therapy that is derived from an animal's own adipose tissue, or fat tissue. Adipose derived stem cells are capable of differentiating into a variety of tissue types including tendon, ligament, bone, cartilage, and muscle, as well as have been proven to reduce pain and inflammation. Vet-Stem introduced this therapy over a decade ago as the answer for horses with tendon injuries facing unfortunate euthanasia due to their injuries. Stem cell therapy showed the ability to offer a new lease on life.
Current uses of Vet-Stem's Regenerative cell therapies include joint issues such as degenerative joint disease, as well as tendon and ligament injuries. Some investigation is also being done toward stem cell use for immune mediated diseases, severe chronic allergies, and other conditions. Stem cell therapy is also being used to regenerate and encourage the healing process alongside arthroscopic surgery in horses. Vet-Stem's stem cell services come with banking of cells for later use, and the opportunity to culture, or grow more cells for retreatment. Often horses suffer from multiple injuries in their career, which can all be injected with their own stem cells to relieve pain and inflammation as well as promote natural healing.
Vet-Stem brought the GenesisCS-2 Component Concentrating System for PRP to market in 2007 as an easy to use, in-house therapy for equine veterinarians to apply to a soft tissue injury or joint issue, to decrease inflammation and pain while stem cells were in culture, or while a performance horse was active and unable to take time off for recovery. PRP in an injury, or area of damaged cells provides a matrix or scaffolding for healing and provides an ideal environment for a concentration of stem cells to be the most effective for positive long term effects.
Equine veterinarians and horse owners turn to Vet-Stem for Regenerative Cell Therapies because 70% of horses with tendon and ligament injuries return to their prior level of performance. This statistic alone promises a successful relationship for Vet-Stem and Animal Health International in offering Regenerative Veterinary Medicine to the national equine industry.
Animal Health International has been serving the needs of the industry for over 40 years, with the broadest offering of products, representing over 1,000 different manufacturing suppliers. Animal Health International stocks and ships quickly from over 70 locations nationwide, and their team of more than 400 representatives are trained and educated with all the latest information on products, programs and protocols. Their goal is the success of their customers.
About Vet-Stem, Inc.
Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.'s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure.
< Back to Press Releases